New Research - Reversing Type 2 diabetes with fast and effective weight loss
Type 2 diabetes is a progressive illness. When someone has type 2 diabetes, their body becomes gradually less able to produce insulin or their body is unable to utilise the insulin they do produce. This leads to high blood glucose levels, which if not corrected can cause damage to the blood vessels, affect eye sight, increase risk of serious health conditions (such as heart attack and stroke) or lead to the development of leg ulcers1.
Australia has one of the highest global rates of diabetes diagnosis worldwide2
Around 1.7 million Australians have diabetes, and 85% of these have type 2 diabetes2
Type 2 diabetes and weight implications
The risk of developing type 2 diabetes is significantly increased for those who are overweight or obese3. As well as following an appropriate diet for blood glucose control, an important part in the management of type 2 diabetes may involve weight loss.4
Reversing Type 2 diabetes with weight loss
Recently a large UK research trial has demonstrated that almost half of those who lost an average of 10kg using a very low calorie diet (VLCD) achieved remission of Type 2 diabetes at 12 months.5 With weight loss between 10-15kg, 57% of those achieved remission at 2 years.5
How can the OPTIFAST VLCD Program help you?
The OPTIFAST VLCD Program can help you achieve fast and effective weight loss with a flexible 3,2,1 step program.
Weight loss has been shown to help:
- Improve blood glucose control5
- Reduce blood cholesterol3
- Improve blood pressure control3
- Improve quality of life5
- Reduce the pain associated with osteoarthritis6
OPTIFAST VLCD and Diabetes Medication
You must consult your doctor or healthcare professional before starting the OPTIFAST VLCD Program, as you may require an adjustment in your medication or insulin dosage, as well as close monitoring of other weight loss markers.
Is OPTIFAST VLCD suitable for Diabetes?
Most overweight and obese patients with Type 1 or Type 2 diabetes are eligible to use OPTIFAST VLCD as part of an overall management program that emphasises the importance of ongoing weight maintenance. You must consult your doctor or healthcare professional before starting the OPTIFAST VLCD Program, as you may require an adjustment in your medication or insulin dosage, as well as close monitoring of other weight loss markers.
GI Values of the OPTIFAST VLCD Range
| Product | GI Value | Carbohydrates(g/serve) |
|---|---|---|
| Shakes | ||
| OPTIFAST VLCD Chocolate Shake | 22 | 18.2 |
| OPTIFAST VLCD Vanilla Flavour Shake | 28 | 18.2 |
| OPTIFAST VLCD Strawberry Flavour Shake | 26 | 18.2 |
| OPTIFAST VLCD Coffee Shake | 25 | 18.2 |
| OPTIFAST VLCD Banana Flavour Shake | 29 | 18.2 |
| OPTIFAST VLCD Caramel Flavour Shake | 24 | 18.2 |
| OPTIFAST VLCD Chai Flavour Shake | 21 | 18.2 |
| OPTIFAST VLCD Mocha Flavour Shake | 23 | 18.2 |
| Desserts | ||
| OPTIFAST VLCD Chocolate Dessert | 20 | 18.2 |
| OPTIFAST VLCD Lemon Crème Flavour Dessert | 21 | 18.2 |
| Soups | ||
| OPTIFAST VLCD Vegetable Soup | 18 | 18.2 |
| OPTIFAST VLCD Chicken Flavour Soup | 21 | 18.2 |
| OPTIFAST VLCD Tomato Country Style Soup | 16 | 18.2 |
| Bars | ||
| OPTIFAST VLCD Chocolate Bar | 19 | 17.5 |
| OPTIFAST VLCD Berry Crunch Flavour Bar | 28 | 22.8 |
| OPTIFAST VLCD Cappuccino Flavour Bar | 23 | 22.2 |
| OPTIFAST VLCD Cereal Bar | 30 | 22.1 |
References:
1. Burden of Diabetes in Australia: it’s time for more action. University of Sydney, preliminary report, July 2018.
2. Diabetes Australia https://www.diabetesaustralia.com.au/diabetesin-australia (accessed 4/7/2019)
3. Anderson, J.W., et al., Importance of Weight Management in Type 2 Diabetes: Review with Metaanalysis of Clinical Studies. Journal of the American College of Nutrition, 2003. 22(5): p. 331-339.
4. National Health and Medical Research Council. Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children in Australia. National Health and Medical Research Council, 2013.
5. Lean M.E.J., et al., Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391: 541–51. 6. Diabetes UK. DiRECT 2nd Year Findings Press Release. Accessed: 25/7/2019. https://www.directclinicaltrial.org.uk/Documents/DiRECT%202nd%20Year%20Findings%20Press%20Release.pdf
